Maria Cristina Morganti-Kossmann

This study shows that FGFR inhibition with Rogaratinib reduces microglia reactivity and synaptic loss in TBI by dampening neuroimmunological responses.

This study identifies cMet/HGFR as a modulator of early neuroinflammation in TBI, showing that its inhibition reduces microglial reactivity and improves recovery.

This study shows that reducing neuronal nuclear calcium signaling after TBI increases microglial reactivity and synaptic loss, mediated by osteoprotegerin.

The paper identifies IL-13 and its receptor as neuronal synaptic proteins that enhance synaptic activity and neuroprotection in response to injury.